INT9327

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1989
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 9
Disease Relevance 5.07
Pain Relevance 2.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (Igf2) extracellular space (Igf2) extracellular region (Igf2)
carbohydrate metabolic process (Igf2)
Anatomy Link Frequency
body 2
liver 1
choroid plexus 1
bowel 1
Igf2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Central nervous system 3 99.98 Very High Very High Very High
dexamethasone 90 99.56 Very High Very High Very High
Serotonin 9 98.52 Very High Very High Very High
fluoxetine 15 98.08 Very High Very High Very High
anesthesia 4 95.32 Very High Very High Very High
Chronic pancreatitis 2 94.60 High High
spastic colon 2 91.72 High High
agonist 7 90.96 High High
Bile 2 60.72 Quite High
Kinase C 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Stress 3 99.38 Very High Very High Very High
Disease 2 97.84 Very High Very High Very High
Hepatocellular Cancer 6 97.72 Very High Very High Very High
Appetite Loss 11 97.32 Very High Very High Very High
Diabetes Mellitus 5 97.16 Very High Very High Very High
Cirrhosis 2 96.72 Very High Very High Very High
Body Weight 15 96.44 Very High Very High Very High
Pancreatic Cancer 2 96.08 Very High Very High Very High
Chronic Hepatitis 2 94.96 High High
Pancreatitis 2 94.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Further, the possibility of serotonergic control of IGF-II secretion was examined by determining IGF-II response to fluoxetine (FLX) injections (15 mg/kg body wt., i.p.).
Localization (secretion) of IGF-II in body associated with fluoxetine
1) Confidence 0.80 Published 1993 Journal Regul. Pept. Section Abstract Doc Link 8265809 Disease Relevance 0.64 Pain Relevance 0.45
These data suggest that a serotonergic influence on CNS IGF-II exists and that IGF-II secretion may be altered by factors affecting serotonin metabolism or efficacy.
Localization (secretion) of IGF-II associated with serotonin
2) Confidence 0.80 Published 1993 Journal Regul. Pept. Section Abstract Doc Link 8265809 Disease Relevance 0.49 Pain Relevance 0.50
In order to assess whether metabolic stress alters central nervous system IGF-II secretion, peptide analysis was conducted in rats exhibiting activity-based anorexia (ABA) compared to exercised-matched, body weight-matched or ad libitum fed controls.
Localization (secretion) of IGF-II in body associated with appetite loss, stress, body weight and central nervous system
3) Confidence 0.80 Published 1993 Journal Regul. Pept. Section Abstract Doc Link 8265809 Disease Relevance 0.63 Pain Relevance 0.34
Insulin-like growth factor II is secreted primarily by the liver and is reported to be transcribed in many primary hepatocellular carcinoma (PHC) cell lines.
Localization (secreted) of Insulin-like growth factor II in liver associated with hepatocellular cancer
4) Confidence 0.68 Published 1989 Journal Dig. Dis. Sci. Section Abstract Doc Link 2537715 Disease Relevance 0.86 Pain Relevance 0.05
Serum IGF-II was not different from controls in any of nonhepatic diseases such as diabetes (1032 +/- 97; 19) pancreatic cancer (1413 +/- 282; 8), chronic pancreatitis (999 +/- 126; 17), peptic ulcer (1186 +/- 43; 11), irritable bowel syndrome (1002 +/- 109; 12), gastrointestinal tract cancer (1250 +/- 216; 21) and chronic renal failure (733 +/- 135; 14).
Localization (Serum) of Serum IGF-II in bowel associated with chronic renal failure, diabetes mellitus, spastic colon, ulcers, pancreatic cancer, gastrointestinal neoplasms, disease and chronic pancreatitis
5) Confidence 0.64 Published 1989 Journal Dig. Dis. Sci. Section Abstract Doc Link 2537715 Disease Relevance 1.45 Pain Relevance 0.22
As assessed by solution hybridization, UA-lig fetuses exhibited significantly higher hepatic IGFBP-1, IGFBP-2, and IGF-II transcript abundance than UA-nonlig controls (increased 110, 50, and 31%, respectively).
Localization (abundance) of IGF-II
6) Confidence 0.46 Published 1992 Journal Pediatr. Res. Section Abstract Doc Link 1408464 Disease Relevance 0.32 Pain Relevance 0.17
In addition, choroid plexus expresses insulin, IGF-I, and IGF-II receptors [11,47]., as well as large amounts of IGF-II that is secreted into the CSF [47].
Localization (secreted) of IGF-II in choroid plexus
7) Confidence 0.10 Published 2003 Journal BMC Neurosci Section Body Doc Link PMC165579 Disease Relevance 0 Pain Relevance 0.09
Dexamethasone treatment was related to reduced IGF-II and IGFBP3 secretion and to an increased IGFBP-1.
Localization (secretion) of IGF-II associated with dexamethasone
8) Confidence 0.03 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721283 Disease Relevance 0.33 Pain Relevance 0.21
In the dexamethasone treated children the secretion of IGF-II and IGFBP-3 was significantly reduced after 3 months of life, whereas IGF-I levels were only slightly, but not significantly reduced.
Localization (secretion) of IGF-II associated with dexamethasone
9) Confidence 0.03 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721283 Disease Relevance 0.36 Pain Relevance 0.34

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox